A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)

• Protocol code: GB002-3101
• EudraCT code: No aplica
• Research group: Pneumology
• Service: Pneumology
• Principal investigator:  López Meseguer, Manuel
• Pathology: Malalties del sistema respiratori
• Phase: Fase III